Skip to main content
Fig. 3 | BMC Dermatology

Fig. 3

From: Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort)

Fig. 3

Percentage of parameters of metabolic syndrome (MS) improved following 12 weeks of treatment in placebo, metformin and pioglitazone groups from baseline (Intention to treat Analysis). Inter-group comparisons for percentage of parameters of metabolic syndrome improved carried out by Chi-square test. * = Placebo vs metformin, † = placebo vs pioglitazone, ‡ = metformin vs pioglitazone; MS = Metabolic syndrome

Back to article page

BMC Dermatology

ISSN: 1471-5945

Contact us